Development of Signal Transduction Modulators for Stroke

Multiple signaling pathways, driven by various molecular mechanisms such as angiogenesis, oxidative stress, autophagy, inflammatory response, cell proliferation, and apoptosis, play critical roles in the pathophysiology of stroke. Elucidation of stroke-related signaling pathways at the proteomic and genomic levels has facilitated the design of drug that act on specific proteins in the signaling cascade, also known as signal transduction modulators. Signal transduction modulators can interfere with the signaling process by blocking cell surface receptors or inhibiting downstream gene expression. Numerous signal transduction modulators are being evaluated worldwide as potential stroke therapies.

Fig. 1. Summary diagram of signaling pathways involved in stroke. Fig. 1 Summary diagram of stroke-related signaling pathways. (Chen, et al., 2023)

Our Signal Transduction Modulator Development Services

Ace Therapeutics is committed to helping clients develop signal transduction modulators for stroke by targeting key molecular mechanisms involved in neuroprotection, inflammation, and neuroregeneration. We provide comprehensive, end-to-end services spanning target discovery, validation, and preclinical evaluation to accelerate the development of innovative stroke therapies for our clients.

Target Discovery and Validation

We help clients identify and validate key signaling pathways and molecular targets involved in stroke pathophysiology.

Analyzing complex signaling networks that drive neuronal injury and repair using cutting-edge technologies such as genomics, proteomics, and bioinformatics.
Validating potential targets in both cellular and animal models of stroke using gene editing tools, RNA interference approaches, and functional assays.

Drug Design and Optimization

Following target validation, our medicinal chemistry and computational biology teams help clients design and optimize signal transduction modulators that can either activate or inhibit specific signaling pathways.

Selective optimization: Reducing off-target effects to improve safety of signal transduction modulators.
Pharmacokinetic optimization: Improving bioavailability, blood-brain barrier penetration, and metabolic stability of signal transduction modulators.

Preclinical Evaluation

Ace Therapeutics offers comprehensive preclinical evaluation services to assess the safety and efficacy of signal transduction modulators.

In vitro studies: Evaluating the effects of signal transduction modulators on neuronal survival, inflammation, and oxidative stress using primary neuronal cultures, organotypic brain slices, and cell-based assays.
In vivo studies: Evaluating the effects of modulators on infarct volume, functional recovery, and biomarker expression in animal models of stroke, such as middle cerebral artery occlusion (MCAO) models.
Mechanism studies: Investigating the molecular mechanisms of drug action using Western blotting, immunohistochemistry, and RNA sequencing.

Types of Signal Transduction Modulators We Can Development

Glutamate receptor antagonists	Angiotensin receptor agonists	Anti-TLR monoclonal antibodies
PPARgamma agonists	GABA receptor agonists	Poly (ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors
Phosphatidylinositol 3-kinase beta (PI3KBEβ) inhibitors	Platelet-activating factor receptor (PAFR) antagonists	Adenosine receptor A3 (ADORA3) agonists
Anti-IL1A monoclonal antibodies	Melanocortin MC1 receptor agonists	5-HT2A receptor agonists
Carbonic anhydrase activators	Progesterone receptor ligands	Cytokine production inhibitors
Anti-CD3 (T-cell surface glycoprotein CD3)	Phospholipase C inhibitors

Leveraging our expertise in molecular biology, medicinal chemistry, and drug discovery, Ace Therapeutics is committed to helping clients design and develop signal transduction modulators for stroke. These drug candidates are designed to selectively inhibit or activate specific signaling molecules, thereby restoring the balance of cellular processes disrupted by stroke. If you are interested in our services, please contact us for more information.

Reference

Chen, B., & Jin, W. (2023). A comprehensive review of stroke-related signaling pathways and treatment in western medicine and traditional Chinese medicine. Frontiers in Neuroscience, 17, 1200061.

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.